RHEACELL announces First Patient In : EB-Haus in Salzburg, Austria starts pivotal study for stem cell therapy

RHEACELL announces "First Patient In": EB-Haus in Salzburg, Austria starts pivotal study for stem cell therapy for severe forms of Epidermolysis bullosa that is longed for by those affected

Related Keywords

Israel ,Austria ,Salzburg ,United Kingdom ,Chile ,Heidelberg ,Baden Wüberg ,Germany ,Argentina ,United States ,Great Britain ,German ,Christoph Ganss ,Vander Beken ,Neuenheimer Feld ,Gmbh Co ,European Medicines Agency ,Intractable Rare Diseases Research ,Health News ,Therapies Committee ,Paul Ehrlich Institute ,Cancer Research ,German Federal Institute For Vaccines ,Proceedings Of The National Academy Sciences ,Therapy Medicinal Products ,Advanced Therapies Committee ,Epidermolysis Bullosa ,Rare Diseases Research ,Reviews Disease Primers ,Investigational Dermatology ,Injury Driven Stiffening ,Dermis Expedites Skin Carcinoma ,National Academy ,Chronic Iron Overload Wounds ,German Federal Institute ,